Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19)
and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced …

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic
predisposition, epidermal barrier disruption, and dysregulation of the immune system are …

Sulfoximines have been largely disregarded in medicinal chemistry for a long time.
However, recently, they have risen to the apparent level of stardom on the drug discovery …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

abstract Atopic dermatitis (AD) is a heterogenous disorder and can be classified into
different types. Stratification of subtypes may enable personalized medicine approaches. AD …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Recent research advancements indicate that atopic dermatitis (AD) is a complex disease
characterized by different subtypes/phenotypes based on age, disease chronicity, ethnicity …

Angiogenesis, the growth of new blood vessels from preexisting vessels, is associated with
inflammation in various pathological conditions. Well-known angiogenetic factors include …

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by
both terminal keratinocyte differentiation defects and strong type 2 immune responses. In …

The heterogeneous course, severity, and treatment responses among patients with atopic
dermatitis (AD; eczema) highlight the complexity of this multifactorial disease. Prior studies …